KR20090089135A - Composition having brain function and congnition enhancing activity comprising betula platy phylla sap - Google Patents

Composition having brain function and congnition enhancing activity comprising betula platy phylla sap Download PDF

Info

Publication number
KR20090089135A
KR20090089135A KR1020080014524A KR20080014524A KR20090089135A KR 20090089135 A KR20090089135 A KR 20090089135A KR 1020080014524 A KR1020080014524 A KR 1020080014524A KR 20080014524 A KR20080014524 A KR 20080014524A KR 20090089135 A KR20090089135 A KR 20090089135A
Authority
KR
South Korea
Prior art keywords
composition
brain function
sap
memory
phylla
Prior art date
Application number
KR1020080014524A
Other languages
Korean (ko)
Other versions
KR100950255B1 (en
Inventor
성상현
김승현
최지현
김영남
이중호
권민수
Original Assignee
에스케이임업 주식회사
주식회사 엘컴사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이임업 주식회사, 주식회사 엘컴사이언스 filed Critical 에스케이임업 주식회사
Priority to KR1020080014524A priority Critical patent/KR100950255B1/en
Publication of KR20090089135A publication Critical patent/KR20090089135A/en
Application granted granted Critical
Publication of KR100950255B1 publication Critical patent/KR100950255B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition for improving brain function and cognitive function is provided to treat or prevent memory, dementia, amnesia or Alzheimer disease using Betula platy phylla liquid solution. A composition for improving brain function and cognition function comprises Betula platy phylla liquid solution only as an active ingredient and pharmaceutically or sitologically acceptable excipient. The composition is used for treating and preventing damage of memory, dementia, amnesia or Alzheimer disease. A health adjuvant food for improving brain function and cognitive function comprises the composition. The food is selected from the forms of tablet, capsule, powder, granule, liquid and beverage.

Description

자작나무 수액을 유효성분으로 함유하는 뇌기능 및 인지 기능 개선용 조성물{Composition having brain function and congnition enhancing activity comprising Betula Platy Phylla sap}Composition having brain function and congnition enhancing activity comprising Betula Platy Phylla sap}

본 발명은 뇌기능 및 인지 기능 개선 활성을 갖는 조성물에 관한 것으로서, 보다 상세하게는 자작나무 수액을 유효성분으로 함유하는 뇌기능 및 인지 기능 개선용 조성물에 관한 것이다.The present invention relates to a composition having a brain function and cognitive function improving activity, and more particularly to a composition for improving brain function and cognitive function containing birch sap as an active ingredient.

최근 노인성 치매가 퇴행성 중추신경계 질환으로 인정되고 그 환자의 수가 날로 증가됨에 따라 커다란 사회적인 문제로 대두되면서 이의 예방이나 개선, 치료에 대한 중요성이 새롭게 부각되고 있다. 노인성 질환 중에서 최근 사회 문제로 까지 대두되고 있는 치매 환자의 대부분이 알츠하이머씨 병 환자인 것으로 알려졌다. 알츠하이머씨(Alzheimer's disease) 병 환자는 콜린성, 아드레날린성, GABA성 및 글루타메이트성 신경 등 거의 모든 신경에 이상이 초래되며, 특히 콜린성 신경의 손실이 가장 심각한 것으로 알려져 있다. 이에 콜린성 신경의 이상을 회복시키거나 개선시키는 방향으로 알츠하이머씨 병의 치료제 개발 연구가 활발히 이루어지고 있다. As senile dementia has recently been recognized as a degenerative central nervous system disease and the number of patients has increased day by day, it has emerged as a big social problem, and the importance of its prevention, improvement and treatment is newly emerging. Alzheimer's disease is known to be the majority of dementia patients that have recently emerged as social problems. Alzheimer's disease patients suffer from abnormalities in almost all nerves, including cholinergic, adrenergic, GABA and glutamate nerves, and the loss of cholinergic nerves is known to be most serious. Therefore, researches for the development of Alzheimer's disease treatments have been actively conducted to restore or improve cholinergic disorders.

실험동물에 스코폴라민(scopolamine)을 투여하여 콜린성 신경계에 이상을 유발시켜 알츠하이머씨 병과 비슷한 상태를 인위적으로 조작할 수 있는 방법이 알려지면서 알츠하이머씨 병의 치료제 개발이 진일보하게 되었다(Flood, J. and Cherkin, A. Scopolamine effects on memory retention in mice, Behav. Neural. Biol. 45: 169-184(1986)). The development of a cure for Alzheimer's disease has been advanced as the method of artificially manipulating the condition similar to Alzheimer's disease by inducing abnormalities in the cholinergic nervous system by administering scopolamine to experimental animals (Flood, J.). and Cherkin, A. Scopolamine effects on memory retention in mice, Behav. Neural. Biol. 45: 169-184 (1986)).

흰쥐에 스코폴라민을 투여하면 콜린성 신경기능의 퇴행과 기억력 상실증이 나타나는 것은 물론, 습득력, 즉각적인 대응법, 활동기억(working memory)에 결함이 나타나는 등 알츠하이머씨 병 환자에게서 나타나는 증상과 유사한 증상이 나타난다(Smith, 1988; Giacobini, E. and Cuadra, G.(1994)). 이러한 증상은 콜린성 신경의 효능제인 아레콜린(arecoline) 및 옥소트레모린(oxotremorine)이나 아세틸콜린의 분해를 억제시킴으로써 세포 내의 아세틸콜린의 농도를 유지시키는 아세틸콜린에스테라제(acetylcholinesterase: AChE) 저해제인 피조스티그민(physostigmine) 등의 투여에 의하여 완화되었다. 실제로 AChE 저해제인 타크린(tacrine)은 임상에서 사용되고 있으나 간독성, 짧은 반감기 및 낮은 생체 내 이용률 등의 문제가 제기되고 있어 새로운 대체약물을 찾기 위한 연구가 활발히 진행되고 있다.The administration of scopolamine in rats is associated with symptoms similar to those in Alzheimer's disease, including degeneration of cholinergic neurons and loss of memory, as well as deficiencies in acquisition, immediate response, and working memory. Smith, 1988; Giacobini, E. and Cuadra, G. (1994)). These symptoms are Pizo, an acetylcholinesterase (AChE) inhibitor that maintains the concentration of acetylcholine in the cell by inhibiting the degradation of arecoline and oxotremorine or acetylcholine, which are agonists of cholinergic neurons. It was alleviated by the administration of physostigmine and the like. Indeed, tacrine, an AChE inhibitor, has been used in the clinic, but studies such as hepatotoxicity, short half-life, and low bioavailability have been raised.

본 발명자들은 새로운 뇌기능 및 인지 기능 개선 활성을 갖는 물질을 찾기 위하여 천연물을 대상으로 이의 활성을 검색하던 중 자작나무 수액이 유의성 있는 뇌기능 및 인지 기능 개선 활성을 갖고 있음을 확인하였다. The present inventors confirmed that birch sap has significant brain and cognitive function improving activity while searching for its activity in natural products to find a substance having new brain function and cognitive function improving activity.

본 발명의 자작나무(Betula Platy Phylla)는 자작나무과에 속하는 낙엽교목 으로서 강원도 이북의 높은 산에 많이 자라지만 일본의 북해도와 중국에도 분포한다. 수액은 흰빛이며 수평으로 벗겨지며, 소지는 암갈색으로 지점이 있다. 잎은 장지에서는 호생하며 단지에서는 2개씩 난다. 삼각상 난형으로 길이 5-7cm, 너비 4-6cm이며 예첨두이다. 넓은 설저 또는 아심장저이며 가장자리에 복거치가 있다. 거의 털이 없으나 잎뒷면 엽액에 갈모가 있는 경우도 있다.The birch (Betula Platy Phylla) of the present invention is a deciduous tree belonging to the birch family and grows in high mountains north of Gangwon-do but is also distributed in the North Sea of Japan and China. The sap is white, peeled horizontally, and the branch is dark brown with a spot. Leaves regenerate in the intestines and two in the complex. Triangular ovate, 5-7cm long, 4-6cm wide, with acute tip. It is a wide tongue or heart bottom and has a marginal value at the edge. There is almost no hair, but there are some hairs on the leaf fluid on the back of the leaf.

자작나무 수액은 글루코즈(glucose)와 프락토우즈(fructose)가 주요 성분이며, 칼륨, 나트륨, 마그네슘, 아연과 같은 무기질이 소량 함유되어 있으며, 아미노산(타우린, 글리신, 라이신, 알라닌, 트레오닌 등), 단백질 외에도 말릭산과 기타 알려지지 않은 성분과 같은 유기산으로 구성되어 있다. 수액은 달고, 맛있고, 상쾌한 맛을 갖고 있어 중국에서는 수년간 자작나무 수액을 모아서 음료로 사용해 왔고, 북유럽에서도 수액이 건강음료로 이용되고 있다. 자작나무 수액의 활성에 관한 연구는 부족한 실정이며 지금까지 자작나무 수액의 뇌기능 및 인지 기능과 관련된 연구는 수행된 바가 없었다. 본 발명에서는 자작나무 수액의 뇌기능 및 인지 기능 개선 활성을 나타냄을 놀랍게도 확인하여 본 발명을 완성하기에 이르렀다. The birch sap is composed mainly of glucose and fructose, and contains small amounts of minerals such as potassium, sodium, magnesium, and zinc, and amino acids (taurine, glycine, lysine, alanine, threonine, etc.), In addition to protein, it consists of organic acids such as malic acid and other unknown constituents. The sap has a sweet, delicious and refreshing taste. In China, birch sap has been collected and used for many years in China, and sap is used as a health drink in Northern Europe. The research on the activity of birch sap is insufficient, and so far, no research on the brain function and cognitive function of birch sap has been conducted. In the present invention, it was surprisingly confirmed that the sap of the birch sap to improve brain function and cognitive function to complete the present invention.

본 발명은 유효성분으로서 자작나무 수액을 단독으로 포함하거나, 약제학적 또는 식품학적으로 허용되는 부형제와 함께 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The present invention provides a composition for improving brain function and cognitive function comprising birch sap alone as an active ingredient, or in combination with a pharmaceutically or food-acceptable excipient.

본 발명은 또한 자작나무 수액을 포함하는 조성물을 함유하는 뇌기능 및 인지 기능 개선 효과를 나타내는 식품첨가물, 건강보조식품, 또는 약제학적 조성물을 제공한다. 상기 건강보조식품, 또는 약제학적 조성물은 정제, 캅셀제, 분말제, 과립제, 액상제 및 음료로 구성된 군으로부터 선택되는 것이 바람직하다.The present invention also provides a food additive, dietary supplement, or a pharmaceutical composition exhibiting a brain and cognitive function improving effect containing a composition comprising birch sap. The dietary supplement or pharmaceutical composition is preferably selected from the group consisting of tablets, capsules, powders, granules, liquids and beverages.

본 발명은 유효성분으로서 자작나무 수액을 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The present invention provides a composition for improving brain function and cognitive function, including birch sap as an active ingredient.

본 발명의 자작나무 수액은 자작나무로부터 통상의 채취 방법을 통해 채취하거나, 시판되는 자작나무 수액, 예컨대, SK 건설(주)의 자작나무 수액(상품명: 행복한 산책)을 구입하여 이를 사용할 수 있다. 또한 상기 채취된 수액을 채취과정상의 변화를 줄이기 위해, 이를 여과등의 처리수단으로 가공한 여과물, 또는 수액을 농축하거나, 동결건조한 분말등도 본 발명의 자작나무 수액으로 사용할 수 있음은 명백하다. The birch sap of the present invention can be collected from a birch through a conventional harvesting method, or a commercially available birch sap, for example, can be used by purchasing a birch sap (trade name: Happy Walk) of SK Construction. In addition, in order to reduce the change in the collected process of the collected sap, it is obvious that the filtrate processed by the processing means such as filtration, or the sap concentrated or lyophilized powder can also be used as the birch sap of the present invention. .

본 발명에 있어서, 상기 자작나무 수액은 하기 실험예와 같이 우수한 뇌기능 및 인지 기능 개선 활성을 나타내었다. In the present invention, the birch sap showed excellent brain function and cognitive function improving activity as in the following experimental example.

본 발명의 조성물은 뇌기능 및/또는 인지 기능 개선 효과를 나타내며, 기억력 상실, 기억력의 손상, 특히 습득력의 결함 및/또는 활동기억 상실과 관련된 기억력의 손상, 치매, 건망증, 알츠하이머씨병 등의 예방 및 치료용 조성물로써 사용할 수 있다. The composition of the present invention exhibits an effect of improving brain function and / or cognitive function, prevents memory loss, memory impairment, in particular memory impairment associated with deficiency of acquisition and / or loss of activity memory, dementia, forgetfulness, Alzheimer's disease, and the like. It can be used as a therapeutic composition.

본 발명의 조성물은 약제학적 또는 식품학적 분야에서 공지의 방법의 의해 제제화될 수 있고, 그 자체 또는 약제학적으로 허용되는 담체, 부형제 등과 혼합하여 약제학적 또는 식품학적으로 통상으로 허용되는 제제, 예를 들면 액제, 시럽제, 캡슐제 등으로 제제화될 수 있으며, 이들은 경구 또는 비경구로 투여될 수 있다.The compositions of the present invention may be formulated by methods known in the pharmaceutical or food arts, and may be used alone or in admixture with pharmaceutically acceptable carriers, excipients, etc. For example, it may be formulated as a liquid, syrup, capsule, and the like, which may be administered orally or parenterally.

상기 본 발명의 조성물을 포함하는 액제, 캡슐제, 음료 등은 건강보조식품으로 사용될 수 있으며, 본 발명에서 사용된, 용어 "건강보조식품"이라 함은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀제, 분말제, 과립제, 액상제, 환제 등의 형태로 제조 가공한 건강식품 또는 음료, 요구르트, 치즈 등의 기능성 식품을 말한다.Liquids, capsules, beverages, etc. comprising the composition of the present invention can be used as a dietary supplement, the term "health supplement" used in the present invention is used as a raw material or ingredient having a useful functionality to the human body Refers to functional foods such as health foods or beverages, yogurt, cheese, etc. manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like.

본 발명의 조성물은 체내에서 활성성분의 흡수도, 배설속도, 환자의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, 일반적으로 자작나무 수액을 적량, 예컨대, 100∼200ml 용량으로 1일 수회 음용하거나, 이의 건조 분말을 성인에게 1일 0.01∼500mg/kg, 바람직하게는 0.1∼200mg/kg으로 투여하는 것이 바람직하다. 이렇게 제형화된 단위투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.The composition of the present invention is appropriately selected depending on the absorption of the active ingredient in the body, the rate of excretion, the age and weight of the patient, the sex and condition, the severity of the disease to be treated, etc. In general, a birch sap in a suitable amount, for example, 100 to 200ml It is preferable to drink several times a day at a dose, or to administer the dry powder thereof to an adult at 0.01 to 500 mg / kg, preferably 0.1 to 200 mg / kg per day. The unit dosage form so formulated may be administered several times at regular time intervals as needed.

이하, 본 발명을 하기 실시예를 통하여 더욱 상세히 설명한다. 이들 실시예는 본 발명의 예시 목적을 위한 것이며, 본 발명의 보호범위를 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are for illustrative purposes of the present invention and are not intended to limit the protection scope of the present invention.

실시예Example 1 One : 시험물질: Test substance

시판 자작나무 수액(SK 건설(주), 상품명: 행복한 산책)을 구입하여, 이를 감압농축 및 동결건조한 후, 분말화하여 하기 실험예에 사용하였다. Commercial birch sap (SK Construction Co., Ltd., trade name: Happy Walk) was purchased, concentrated under reduced pressure and lyophilized, and then powdered and used in the following experimental example.

실험예Experimental Example 1 One

1. 실험 방법1. Experiment Method

1) 실험동물1) Experimental Animal

서울대학교 실험동물 사육실에서 충분한 물과 사료로 사육한 25-30g의 ICR계 마우스(male)를 공급받아 1주일 동안 실험실 환경에 적응시킨 후 실험에 사용하였다.Seoul National University experimental animal breeding room was supplied with 25-30g of ICR male (male) reared with sufficient water and feed was used for the experiment after being adapted to the laboratory environment for one week.

2) 수동적 회피반응 측정(Passive avoidance test)2) Passive avoidance test

하단에 두께 3mm의 스테인레스 막대가 0.5cm 간격으로 설치된 회피상자(40 X 20 X 20 cm)를 밝은 방과 어두운 방으로 나누고 밝은 방에 넣은 마우스가 어두운 방으로 들어갔을 때 스테인레스 막대를 통하여 0.2 mA/10g 체중의 전기자극을 주는 훈련을 시켰다. 24시간 후 동일한 시험을 실시하여 마우스가 밝은 방에 머무르는 시간(Step through latency)을 측정하여 전일의 훈련을 기억하는 지표로 하여 실시예 1의 투여군, 콘트롤군 및 대조군 투여군을 비교하였다. 스코폴라민을 생리식염 수에 녹여 1.5mg/kg의 용액을 제조하여 훈련시행 30분전에 피하주사하여 기억력 및 인지기능 손상을 유발시키며, 스코폴라민 투여 1시간 30분 전에 실시예 1의 자작나무 수액을 생리식염수에 녹여 30mg/ml, 50mg/ml, 100mg/ml으로 각각 구강투여 하여 스코폴라민에 의해 유도된 기억력 및 인지기능 손상에 어떤 영향을 미치는지를 관찰하였다.Split the evacuation box (40 X 20 X 20 cm) with a 3 mm thick stainless steel bar at the bottom into a bright and dark room, and 0.2 mA / 10 g through the stainless bar when the mouse in the bright room enters the dark room. I trained to give an electrical stimulus of my weight. After 24 hours, the same test was performed to measure the time the mouse stays in a bright room (Step through latency), and compared with the administration group, the control group, and the control group of Example 1 as an index for remembering the training of the previous day. Scopolamine was dissolved in physiological saline to prepare a solution of 1.5 mg / kg and injected subcutaneously 30 minutes prior to training to cause memory and cognitive impairment, and the birch of Example 1 1 hour 30 minutes before scopolamine administration The sap was dissolved in physiological saline and orally administered at 30 mg / ml, 50 mg / ml, and 100 mg / ml, respectively, to observe the effects on the memory and cognitive impairment induced by scopolamine.

그 결과를 도 1에 나타내었다. 도 1에 있어서, "콘트롤"은 스코폴라민과 자작나무 수액을 모두 먹이지 않은 정상군에 해당하여, "스코폴라민"은 대조군으로서, 실시예 1에서 제조한 자작나무 수액을 처리하지 않고 오직 스코폴라민으로만 처리하여 기억력 및 인지기능 손상을 유발한 군에 해당한다.The results are shown in FIG. In Figure 1, "control" corresponds to the normal group not fed both scopolamine and birch sap, "scopolamine" as a control, without treating the birch sap prepared in Example 1 It is the group that treated with only polyamine and caused memory and cognitive impairment.

도 1에서 나타난 바와 같이, 스코폴라민에 의하여 유도된 기억력 및 인지기능 손상을 유도한 마우스의 수동적 회피반응 테스트에서 자작나무 수액을 30mg/ml, 50mg/ml, 100mg/ml로 섭취시켰을 때 스텝 쓰루 레이턴시(Step through latency)가 농도 의존적으로 각각 35.5%, 53.3%, 76.4%으로 회복율이 증가하였다. 이와 같이, 자작나무 수액이 기억력 및 인지기능 손상에 있어 유의성 있는 효과를 나타냄을 알 수 있다. As shown in Fig. 1, step through when birch sap was ingested at 30 mg / ml, 50 mg / ml, and 100 mg / ml in a passive avoidance reaction test of mice induced memory and cognitive impairment induced by scopolamine. The recovery rate increased to 35.5%, 53.3%, and 76.4%, depending on the concentration. Thus, it can be seen that birch sap has a significant effect on memory and cognitive impairment.

조성물 Composition 실시예Example

조성물예Composition example 1. 캡슐제의 제조 1. Preparation of Capsule

실시예 1의 자작나무 수액 200mg200 mg of birch sap of Example 1

유당 100mgLactose 100mg

전분 93mgStarch 93mg

탈크 2mgTalc 2mg

스테아린산 마그네슘 적량Magnesium stearate proper amount

상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.

조성물예Composition example 2. 캡슐제의 제조 2. Preparation of Capsule

실시예 1의 자작나무 수액 100mg100 mg of birch sap of Example 1

유당 100mgLactose 100mg

전분 93mgStarch 93mg

탈크 2mgTalc 2mg

스테아린산 마그네슘 적량Magnesium stearate proper amount

상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.

도 1은 본 발명의 자작나무 수액에 대한 기억력 회복 효과를 나타낸 도면이다. 1 is a view showing the memory recovery effect on the birch sap of the present invention.

Claims (5)

유효성분으로서 자작나무 수액을 단독으로 포함하거나, 약제학적 또는 식품학적으로 허용되는 부형제와 함께 포함하는 뇌기능 및 인지 기능 개선용 조성물. A composition for improving brain function and cognitive function comprising birch sap alone as an active ingredient or together with a pharmaceutically or food-acceptable excipient. 제1항에 있어서, 상기 조성물이 기억력 상실, 습득력의 결함과 활동기억 상실과 관련된 기억력의 손상, 치매, 건망증 또는 알츠하이머씨병의 치료 또는 예방을 위한 것인 조성물. The composition of claim 1, wherein the composition is for the treatment or prevention of memory impairment associated with loss of memory, deficiency of acquisition and loss of activity memory, dementia, forgetfulness or Alzheimer's disease. 제1항의 조성물을 함유하는 뇌기능 및 인지 기능 개선용 건강보조식품. Health supplement foods for improving brain function and cognitive function containing the composition of claim 1. 제3항에 있어서, 건강보조식품이 정제, 캅셀제, 분말제, 과립제, 액상제 및 음료로 구성된 군으로부터 선택된 것인 건강보조식품.The dietary supplement of claim 3, wherein the dietary supplement is selected from the group consisting of tablets, capsules, powders, granules, liquids and beverages. 제1항의 조성물을 함유하는 뇌기능 및 인지 기능 개선용 약제학적 조성물. A pharmaceutical composition for improving brain function and cognitive function containing the composition of claim 1.
KR1020080014524A 2008-02-18 2008-02-18 Composition having congnition enhancing activity comprising Betula Platy Phylla sap KR100950255B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080014524A KR100950255B1 (en) 2008-02-18 2008-02-18 Composition having congnition enhancing activity comprising Betula Platy Phylla sap

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080014524A KR100950255B1 (en) 2008-02-18 2008-02-18 Composition having congnition enhancing activity comprising Betula Platy Phylla sap

Publications (2)

Publication Number Publication Date
KR20090089135A true KR20090089135A (en) 2009-08-21
KR100950255B1 KR100950255B1 (en) 2010-03-31

Family

ID=41207485

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080014524A KR100950255B1 (en) 2008-02-18 2008-02-18 Composition having congnition enhancing activity comprising Betula Platy Phylla sap

Country Status (1)

Country Link
KR (1) KR100950255B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200112541A (en) 2019-03-22 2020-10-05 이학봉 Antiobesity composition comprising birch extract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06311868A (en) * 1993-04-28 1994-11-08 Isukura Sangyo Kk Food liquid composed mainly of white birch sap
US20060014704A1 (en) 2004-07-16 2006-01-19 Landry Donald W Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production
JP5068952B2 (en) 2006-02-16 2012-11-07 株式会社コーセー Involucrin production promoter

Also Published As

Publication number Publication date
KR100950255B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
US8492442B2 (en) Medicinal composition, food or drink having effect of enhancing parasympathetic nervous activity
CN102438642A (en) Composition comprising green tea extract
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
TW201828955A (en) Anti-fatigue composition used for increasing endurance performance
EP2990048B1 (en) Nitric oxide concentration elevating agent
WO2007007993A1 (en) Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract
KR20110005144A (en) Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects
KR20160107420A (en) A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease
JP2014237715A (en) Agent for alleviating alcoholic fatigue
WO2005087022A1 (en) Food composition having antistress effect
KR100950255B1 (en) Composition having congnition enhancing activity comprising Betula Platy Phylla sap
KR20140077483A (en) Composition for preventing or treating the brain ischemia disease containing extract of glehnia littoralis
KR20160100279A (en) Anti-cancer composition containing erythronium japonicum extract
US20100074975A1 (en) Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract
KR20120113924A (en) Composition comprising extract of daphne genkwa as active ingradient
KR101870280B1 (en) A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole
JPH07228539A (en) Extrct from leaf lagerstroemia speciosa and antidiabetic agent
KR101852583B1 (en) Composition for preventing the ischemic stroke disease containing populus tomentiglandulosa extract
KR20210146590A (en) Pharmaceutical composition for preventing or treating cancer comprising belamcandae rhizoma extract as an active ingredient
KR20110004691A (en) Pharmaceutical composition and health-food composition containing extract from rhus chinensis having improvement-effect of brain-fuction
KR101780718B1 (en) Pharmaceutical composition for preventing or treating diabetes mellitus comprising seed extract of platycodon
JP2007045750A (en) Anti-fatigue agent
KR100950254B1 (en) Composition having congnition enhancing activity comprising Betula Platy Phylla extract
KR20130065117A (en) Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity
KR20130065127A (en) Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130315

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20140312

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160318

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20170104

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190325

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20200130

Year of fee payment: 11